ACRS
Aclaris Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$6.17
+3.70%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+39.7%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 4, 2026 | Kolbeck Roland Wilhelm · officer: Chief Scientific Officer | F-InKind | 12,385 | $5.20 |
| Aug 4, 2026 | Kolbeck Roland Wilhelm · officer: Chief Scientific Officer | M-Exempt | 36,375 | $0.00 |
| Jun 8, 2026 | MILANO VINCENT · director | A-Award | 10,987 | $0.00 |
| Jun 8, 2026 | SCHIFF ANDREW N · director | M-Exempt | 11,580 | $0.00 |
| Jun 8, 2026 | Humphries William D. · director | M-Exempt | 11,580 | $0.00 |
| Jun 8, 2026 | Mehra Anand · director | A-Award | 42,350 | $4.71 |
| Jun 8, 2026 | Molineaux Christopher P. · director | A-Award | 42,350 | $4.71 |
| Jun 8, 2026 | SCHIFF ANDREW N · director | A-Award | 10,987 | $0.00 |
| Jun 8, 2026 | GOWEN MAXINE · director | M-Exempt | 11,580 | $0.00 |
| Jun 8, 2026 | Mehra Anand · director | M-Exempt | 11,580 | $0.00 |
| Jun 8, 2026 | MILANO VINCENT · director | M-Exempt | 11,580 | $0.00 |
| Jun 8, 2026 | Molineaux Christopher P. · director | A-Award | 10,987 | $0.00 |
| Jun 8, 2026 | Molineaux Christopher P. · director | M-Exempt | 11,580 | $0.00 |
| Jun 8, 2026 | SCHIFF ANDREW N · director | A-Award | 42,350 | $4.71 |
| Jun 8, 2026 | GOWEN MAXINE · director | A-Award | 10,987 | $0.00 |
| Jun 8, 2026 | MILANO VINCENT · director | A-Award | 42,350 | $4.71 |
| Jun 8, 2026 | GOWEN MAXINE · director | A-Award | 42,350 | $4.71 |
| Jun 8, 2026 | Mehra Anand · director | A-Award | 10,987 | $0.00 |
| Jun 8, 2026 | Humphries William D. · director | A-Award | 10,987 | $0.00 |
| Jun 8, 2026 | Humphries William D. · director | A-Award | 42,350 | $4.71 |
| May 5, 2026 | Hall Jesse Wayne · officer: Chief Medical Officer | F-InKind | 9,330 | $4.41 |
| May 5, 2026 | Hall Jesse Wayne · officer: Chief Medical Officer | M-Exempt | 36,375 | $0.00 |
| Apr 27, 2026 | Leonard Braden Michael · 10 percent owner | Sale | 300,000 | $4.53 |
| Feb 6, 2026 | Walker Neal · director, officer: CEO | A-Award | 961,700 | $3.61 |
| Feb 6, 2026 | Hall Jesse Wayne · officer: Chief Medical Officer | A-Award | 343,300 | $3.61 |
| Feb 6, 2026 | Kolbeck Roland Wilhelm · officer: Chief Scientific Officer | A-Award | 95,700 | $0.00 |
| Feb 6, 2026 | Davis Hugh M. · director, officer: President and COO | A-Award | 336,300 | $3.61 |
| Feb 6, 2026 | Balthaser Kevin · officer: Chief Financial Officer | A-Award | 99,100 | $0.00 |
| Feb 6, 2026 | Balthaser Kevin · officer: Chief Financial Officer | A-Award | 346,800 | $3.61 |
| Feb 6, 2026 | Kolbeck Roland Wilhelm · officer: Chief Scientific Officer | A-Award | 334,900 | $3.61 |
Institutional positioning
13F filings over the trailing two quarters
New 62Increased 106Reduced 76Sold out 15
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | Unchanged | 14,250,000 | May 6, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Increased | 12,723,026 | Aug 14, 2026 |
| BML Capital Management, LLC | Reduced | 11,975,000 | Aug 7, 2026 |
| BlackRock, Inc. | Increased | 10,037,008 | Aug 7, 2026 |
| DEEP TRACK CAPITAL, LP | New Position | 9,345,000 | May 15, 2026 |
| Deep Track Capital, LP | Unchanged | 9,345,000 | Aug 14, 2026 |
| BLACKROCK, INC. | Increased | 7,407,065 | May 13, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | New Position | 6,804,072 | May 15, 2026 |
| Vivo Capital, LLC | Increased | 6,694,637 | Aug 14, 2026 |
| VIVO CAPITAL, LLC | Reduced | 6,666,666 | May 20, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 5,817,866 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 5,167,469 | May 15, 2026 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | New Position | 4,925,374 | May 15, 2026 |
| Frazier Life Sciences Management, L.P. | Unchanged | 4,925,374 | Aug 14, 2026 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | Increased | 4,472,650 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 4, 2026